CDIO Stock Overview
Develops and commercializes epigenetics-based clinical tests for cardiovascular disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cardio Diagnostics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.27 |
| 52 Week High | US$3.56 |
| 52 Week Low | US$0.19 |
| Beta | 4.68 |
| 11 Month Change | 23.44% |
| 3 Month Change | -37.12% |
| 1 Year Change | -86.73% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.30% |
Recent News & Updates
Shareholder Returns
| CDIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.1% | 2.4% | 2.2% |
| 1Y | -86.7% | 16.2% | 31.7% |
Return vs Industry: CDIO underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: CDIO underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| CDIO volatility | |
|---|---|
| CDIO Average Weekly Movement | 20.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CDIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CDIO's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 8 | Meesha Dogan | cardiodiagnosticsinc.com |
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Cardio Diagnostics Holdings, Inc. Fundamentals Summary
| CDIO fundamental statistics | |
|---|---|
| Market cap | US$7.57m |
| Earnings (TTM) | -US$8.25m |
| Revenue (TTM) | US$35.69k |
227.6x
P/S Ratio-1.0x
P/E RatioIs CDIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDIO income statement (TTM) | |
|---|---|
| Revenue | US$35.69k |
| Cost of Revenue | US$0 |
| Gross Profit | US$35.69k |
| Other Expenses | US$8.29m |
| Earnings | -US$8.25m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 100.00% |
| Net Profit Margin | -23,125.63% |
| Debt/Equity Ratio | 0% |
How did CDIO perform over the long term?
See historical performance and comparison